Comment by
MrMugsy on Aug 13, 2021 3:09pm
I don't think the company believes it's patient specific - way past that - but let's see what the September's update includes. If the drug is more potent than even they expected, they need to find the lowest effective dose. You wouldn't want to go to Phase 3 and run into an FDA stoppage.
Comment by
nozzpack on Aug 13, 2021 4:02pm
U know nothing about what the company thinks. There are many issues related to anomalous and transient LFS from flawed patient selection to idiopathic presents. Surely FDA has never genuflected in the past..
Comment by
MrMugsy on Aug 13, 2021 5:38pm
hahaha. that's pretty agressive NOZZ. you say that with such confidence Who's genuflecting?
Comment by
3burtc on Aug 13, 2021 8:41pm
Yes it does prevent phase3. You see friend if they don't figure out what went wrong. Phase 3 will fail and there goes 60 million. So many questions now about mgnt, especially Wallace. These guy's have lost the confidence of the investment community and it will be tough to regain that trust. I wonder what Nuance thinks? They put up 27 million cdn and now this?
Comment by
Daydream2 on Aug 14, 2021 11:25am
Also what does Bloom & Burton Co. thinks of all this. A few of their tens of millions in investment have evaporated.
Comment by
WalkOverTheStrt on Aug 14, 2021 5:56pm
It's a numbers game to the BPs and investment funds.. Do you really think they had everything at stake on antibe.... Claculated risk and with it many other plays that will pan out. Also Antobe's story is not over and far from it. Delayed yes but HS2 likely has a place in the medical world...